Latest news about Makers Laboratories
Makers Laboratories
148.25
0.00(0.00%)
Company Performance:
View Company Insights1D0.00%
1M+4.29%
6M+26.01%
1Y-4.94%
5Y-26.75%
More news about Makers Laboratories
05May 26
Makers Laboratories Schedules Board Meeting on May 26, 2026 to Approve Q4FY26 Audited Financial Results
Makers Laboratories has scheduled a Board of Directors meeting on Tuesday, May 26, 2026, to consider and approve audited financial results for the 4th quarter and financial year ended March 31, 2026, as per Regulation 29 read with Regulation 47 of SEBI (LODR) Regulations, 2015. The intimation was filed on May 5, 2026, by Company Secretary Piyush Ajmera. In line with SEBI insider trading norms, the trading window for company insiders remains closed from April 1, 2026, and will reopen 48 hours after the declaration of results, i.e., till May 28, 2026.
06Apr 26
Makers Laboratories Limited Submits SEBI Compliance Certificate for Q4FY26
Makers Laboratories Limited submitted its Q4FY26 compliance certificate under SEBI Regulation 74(5) to BSE on April 6, 2026. The filing includes confirmation from registrar MUFG Intime India regarding proper handling of dematerialised securities during the quarter ended March 31, 2026, demonstrating the company's adherence to regulatory requirements.
11Feb 26
Makers Laboratories Reports Strong Q3FY26 Performance with 28.8% Revenue Growth
Makers Laboratories Limited reported strong Q3FY26 consolidated results with revenue growing 28.8% YoY to ₹3,566.76 lakhs and net profit after tax surging 733.9% to ₹226.82 lakhs. Nine-month consolidated revenue increased 20.7% to ₹10,484.31 lakhs, though nine-month PAT declined 53.9% to ₹430.13 lakhs. The company's earnings per share improved significantly to ₹3.84 in Q3FY26 from negative ₹0.50 in Q3FY25, while standalone operations showed mixed performance with revenue growth but continued losses.
21Jan 26
Makers Laboratories Limited Board Meeting Scheduled for February 10, 2026 to Consider Q3FY26 Unaudited Financial Results
Makers Laboratories Limited has scheduled its Board of Directors meeting for February 10, 2026, to consider Q3FY26 and nine-month unaudited financial results ending December 31, 2025. The company notified BSE Limited on January 21, 2026, in compliance with SEBI regulations. Trading window for insiders remains closed from January 1, 2026, until February 12, 2026, extending 48 hours post-results declaration as per SEBI insider trading regulations.
07Nov 25
Makers Laboratories Reports Mixed Q2 FY26 Results: Standalone Loss Amid Revenue Growth
Makers Laboratories Limited reported mixed Q2 FY26 results. Standalone revenue increased 34.7% YoY to ₹1,372.68 crore, but resulted in a net loss of ₹6.18 crore. Consolidated revenue grew 16.8% to ₹3,453.11 crore, with net profit declining 41.9% to ₹74.70 crore. The chemical manufacturing segment remained profitable, while the pharmaceutical segment reported a loss. Half-year standalone results showed 10.8% revenue growth but a net loss of ₹70.86 crore.
11Aug 25
Makers Laboratories Reports 18.3% Revenue Growth and Return to Profitability in Q1
Makers Laboratories Ltd announced Q1 results, showing significant improvement. Total income from operations increased 18.3% to Rs. 3,500.10 lakhs. The company returned to profitability with a net profit after tax of Rs. 128.61 lakhs, compared to a loss of Rs. 70.39 lakhs in the previous year. Net profit before tax rose 371% to Rs. 197.63 lakhs. Earnings per share improved to Rs. 0.74 from a loss of Rs. 1.67. The company's standalone performance also showed improvement, reducing losses. Equity share capital remained stable at Rs. 590.04 lakhs.
08Aug 25
Makers Laboratories Reports Mixed Q1 Results: Standalone Loss, Consolidated Profit
Makers Laboratories Ltd reported mixed Q1 financial results. Standalone operations showed a net loss of Rs 121.89 crore and 21% lower revenue at Rs 970.07 crore. However, consolidated results improved with a net profit of Rs 43.67 crore, despite a 15.5% decrease in revenue to Rs 2,959.17 crore. The Chemical Manufacturing segment outperformed the Pharmaceutical segment, contributing significantly to the consolidated profit. CEO Samhita Parikh emphasized the company's commitment to improving operational efficiency and capitalizing on growth opportunities.
Industry Peers
Sun Pharmaceutical
Divis Laboratories
Torrent Pharmaceuticals
Cipla
Zydus Life Science
Lupin
Mankind Pharma
Dr Reddys Laboratories
Aurobindo Pharma
Laurus Labs
1,935.50
(-0.17%)
6,836.00
(+0.34%)
4,901.50
(+0.07%)
1,439.40
(-0.13%)
1,150.80
(-0.71%)
2,496.30
(-0.28%)
2,525.10
(-0.27%)
1,244.30
(-1.36%)
1,564.70
(-1.43%)
1,537.80
(+2.02%)
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
